Country: Malta
Language: English
Source: Medicines Authority
BUSERELIN
Sanofi Malta Limited Level2, Fort Business Centre, Mriehel Bypass, Birkirkara, Malta
L02AE01
BUSERELIN 100 µg
NASAL SPRAY, SOLUTION
BUSERELIN 100 µg
POM
ENDOCRINE THERAPY
Withdrawn
2006-08-17
PACKAGE LEAFLET: INFORMATION FOR THE USER SUPREFACT 100MICROGRAMS NASAL SPRAY SOLUTION (Buserelin acetate) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please inform your doctor or pharmacist. IN THIS LEAFLET: 1. What Suprefact Nasal Spray is and what it is used for 2. Before you use Suprefact Nasal Spray 3. How to use Suprefact Nasal Spray 4. Possible side effects 5. How to store Suprefact Nasal Spray 6. Further information 1. WHAT SUPREFACT NASAL SPRAY IS AND WHAT IT IS USED FOR Suprefact Nasal Spray contains a medicine called Buserelin acetate. This belongs to a group of medicines called gonadotropin releasing hormone analogues. This is a synthetic version of a hormone that occurs naturally in the body. It works by lowering the production of sex hormones. It is used to treat prostate cancer by lowering the amount of the hormone ‘testosterone’. Before you use Suprefact Nasal Spray 2. WHAT YOU NEED TO KNOW BEFORE YOU USE SUPREFACT NASAL SPRAY DO NOT USE THIS MEDICINE AND TELL YOUR DOCTOR IF: - You are allergic (hypersensitive) to: Buserelin Other similar medicines such as goserelin Any of the other ingredients of Suprefact Nasal Spray (listed in Section 6 below) Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT SUPREFACT NASAL SPRAY SOLUTION 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Suprefact nasal spray contains 100 micrograms buserelin as buserelin acetate in 1 spray dose (100 mg) of aqueous solution containing benzalkonium chloride as preservative. 1.00 mg buserelin is equivalent to 1.05 buserelin acetate. 3. PHARMACEUTICAL FORM Nasal spray solution 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment of advanced hormone dependent prostatic carcinoma (stage C or stage D according to the classification of Murphy _et al_. in Cancer, 45, p 1889-95, 1980) in which suppression of testosterone is indicated; however, not after bilateral orchiectomy (no further reduction of testosterone level by buserelin to be expected). Buserelin acts by blockade and subsequent down-regulation of pituitary LH-RH receptor synthesis. Gonadotropin release is consequently inhibited. As a result of this inhibition there is reduced stimulation of testosterone secretion and serum testosterone levels fall to the castration range. Before inhibition occurs there is a brief stimulatory phase during which testosterone levels may rise. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Initiation of therapy:_ is most conveniently carried out in hospital; 0.5 ml Suprefact injection should be injected subcutaneously at 8 hourly intervals for 7 days. _Maintenance therapy:_ on the 8th day of treatment the patient is changed to intranasal administration of Suprefact. One spray dose is introduced into each nostril 6 times a day according to the following schedule: 1st dose before breakfast 2nd dose after breakfast 3rd and 4th doses before and after midday meal 5th and 6th doses before and after evening me Read the complete document